Effectiveness of human menopausal gonadotropin versus recombinant follicle- stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive.

Slides:

Advertisements

Similar presentations

Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles Ryan G. Steward,

Advertisements

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Time to pregnancy after a previous miscarriage in subfertile couples

Pregnancy outcome after preimplantation genetic screening or natural conception in couples with unexplained recurrent miscarriage: a systematic review.

Couples dropping out of a reimbursed intrauterine insemination program: what is their prognostic profile and why do they drop out? Inge M. Custers, M.D.,

Effectiveness of intrauterine insemination in subfertile couples with an isolated cervical factor: a randomized clinical trial Pieternel Steures, M.D.,

Performance of the postwash total motile sperm count as a predictor of pregnancy at the time of intrauterine insemination: A meta-analysis Janne-Meije.

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.

Esther Leushuis, M. D. , Jan Willem van der Steeg, Ph. D. , M. D

IVF with planned single-embryo transfer versus IUI with ovarian stimulation in couples with unexplained subfertility: an economic analysis Minouche M.E.

Can noninvasive diagnostic tools predict tubal rupture or active bleeding in patients with tubal pregnancy? Ben W.J Mol, M.D., Petra J Hajenius, M.D.,

Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition Lorraine Dennerstein,

Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome: a retrospective case control study Arianna D'Angelo, M.D., Rachel.

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Esther Leushuis, M. D. , Jan Willem van der Steeg, M. D

Pregnancy outcome after preimplantation genetic screening or natural conception in couples with unexplained recurrent miscarriage: a systematic review.

"Patient-centered fertility treatment": what is required?

Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D

Effect of the initiation of progesterone supplementation in in vitro fertilization–embryo transfer outcomes: a prospective randomized controlled trial

Couples with unexplained subfertility and unfavorable prognosis: a randomized pilot trial comparing the effectiveness of in vitro fertilization with elective.

A differential cytokine expression profile is induced by highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone in.

A comparison of blood spot vs

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating.

Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian.

Corifollitropin alfa versus recombinant follicle-stimulating hormone: an individual patient data meta-analysis Georg Griesinger, Robert Boostanfar, Keith.

Chao-Chin Hsu, M. D. , Ph. D. , Hsin-Chih Kuo, Ph. D

A prospective randomized clinical trial of differing starter doses of recombinant follicle- stimulating hormone (follitropin-β) for first time in vitro.

Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection.

Establishing reference values for age-related spermatogonial quantity in prepubertal human testes: a systematic review and meta-analysis Ieva Masliukaite,

Are serum human chorionic gonadotropin clearance curves of use in monitoring methotrexate treatment in cervical pregnancy? Petra J. Hajenius, M.D., Daphne.

Recombinant Follicle-Stimulating Hormone (Follitropin Beta, Puregon) Yields Higher Pregnancy Rates in In Vitro Fertilization than Urinary Gonadotropins

Clinical Assessment of Recombinant Human Follicle-Stimulating Hormone in Stimulating Ovarian Follicular Development Before In Vitro Fertilization fn1

Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis Laura P. Smith, M.D.,

Tomer Singer, M. D. , David H. Barad, M. D. , M. S

Selection of embryos for transfer in IVF: ranking embryos based on their implantation potential using morphological scoring Laura van Loendersloot, Madelon.

Mohamed Fawzy, M. D. , Mohamed Y. AbdelRahman, M. D. , Mohamed H

Does exogenous LH in ovarian stimulation improve assisted reproduction success? An appraisal of the literature Micah J. Hill, Gary Levy, Eric D. Levens

Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist N. Rollene, M. Amols, S. Hudson,

Effect of letrozole at 2. 5 mg or 5

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Rina Agrawal,

Time to pregnancy after a previous miscarriage in subfertile couples

Melatonin supplementation during controlled ovarian stimulation for women undergoing assisted reproductive technology: systematic review and meta-analysis.

Eva Balkenende, Taghride Dahhan, M. D. , Fulco van der Veen, M. D, Ph

Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis

The additional value of ovarian hyperstimulation in intrauterine insemination for couples with an abnormal postcoital test and a poor prognosis: a randomized.

Prospective cohort study of three- versus two-dimensional ultrasound for prediction of oocyte maturity Doron Shmorgun, M.D., Edward Hughes, M.D., Patrick.

Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone.

Comparison of basal follicle-stimulating hormone versus the clomiphene citrate challenge test for ovarian reserve screening Tarun Jain, M.D., Michael.

Are gestational age and endometrial thickness alternatives for serum human chorionic gonadotropin as criteria for the diagnosis of ectopic pregnancy?

A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro.

Effectiveness of highly purified human menopausal gonadotropin vs

Regulation of assisted reproductive technologies in the United States

Cost-effectiveness of hysterosalpingography, laparoscopy, and Chlamydia antibody testing in subfertile couples Ben W.J Mol, M.D., Ph.D., John A Collins,

Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.

Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection.

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome Madelon van Wely, Ph.D.,

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.

Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis Ernesto Bosch, M.D., Elena.

Economic evaluation of highly purified menotropin compared with recombinant follicle- stimulating hormone in assisted reproduction Adam Lloyd, M.Phil.,

Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.

Early menopause in mothers of children with Down syndrome?

Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles

A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders Hakan Cakmak, M.D., Nam D. Tran,

Parental attitudes toward fertility preservation in boys with cancer: context of different risk levels of infertility and success rates of fertility restoration

Thyroid function after controlled ovarian hyperstimulation in women with and without the hyperstimulation syndrome Kris Poppe, M.D., Ph.D., David Unuane,

Systemic methotrexate therapy versus laparoscopic salpingostomy in patients with tubal pregnancy. Part I. Impact on patients’ health-related quality of.

Systemic methotrexate therapy versus laparoscopic salpingostomy in tubal pregnancy. Part II. Patient preferences for systemic methotrexate Pythia T Nieuwkerk,

Effect of obesity on recombinant follicle-stimulating hormone absorption: subcutaneous versus intramuscular administration Michael P Steinkampf, M.D.,

Presentation transcript:

Effectiveness of human menopausal gonadotropin versus recombinant follicle- stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis Madelon van Wely, M.Sc., Lars G Westergaard, M.D., Patrick M.M Bossuyt, Ph.D., Fulco van der Veen, M.D. Fertility and Sterility Volume 80, Issue 5, Pages 1086-1093 (November 2003) DOI: 10.1016/S0015-0282(03)02187-3

FIGURE 1 Summary data of dichotomous outcomes. OHSS = ovarian hyperstimulation syndrome; rFSH = recombinant FSH; RR = relative risk. van Wely. Effectiveness of hMG vs. rFSH. Fertil Steril 2003. Fertility and Sterility 2003 80, 1086-1093DOI: (10.1016/S0015-0282(03)02187-3)